inpatients and outpatients and (2) there is increasing resistance of GNB to the most frequently used antibiotics in hospitalized PV patients.

Because of an impaired response to oral antibiotics, fluid and electrolytic alterations and/or severe sepsis, 10% to 15% of patients with PV are admitted to our service. It is possible that the increasing resistance observed in our study in inpatients is due to an increase in pathogenicity of the bacteria (community-acquired ESBL producers) and/or a decreased response to oral antibiotics (inherent resistance or acquired β-lactamase and/or ESBL related to invasive procedures, mainly catheters, prolonged hospital stay, and confinement in an inpatient unit).3,4

Data about the clinical epidemiology of GNB, compared with GP bacteria, are limited. Infections and severe sepsis in PV are frequently due to GP bacteria; however, GNB are emerging as important pathogens among severely ill patients,5 including those with PV.

The resistance observed in our study can be explained on the basis of the hospital environment, the quality of inpatient care, and the frequency of prescribing antibiotics as outpatients (which is often done on an empiric basis). Antibiotic prescriptions should be justified with microbiological studies; this will lead to the use of specific antibiotics in a given case and is more scientifically sound than empiric prescribing.

Andrés Tirado-Sánchez, MD, MSc, Alejandro Bonifaz, MSc, and Rosa María Ponce-Olivera, MD, MSc
Department of Dermatology, Hospital General de México, México, Distrito Federal

Funding sources: None.

Conflicts of interest: None declared.

Correspondence to: Andrés Tirado-Sánchez, MD, MSc, Servicio de Dermatología, Hospital General de México, Dr. Balmis 148, Col. Doctores, C.P. 06726, México, Distrito Federal

E-mail: atsdermahgm@gmail.com

REFERENCES


Dermatologist response rates to a mailed questionnaire: A randomized trial of monetary incentives

To the Editor: Although surveys are frequently used to collect data from dermatologists, response rates are often low, limiting the generalizability of results.1 Monetary incentives have improved physician survey response but have not been tested in dermatologists.2 Moreover, the effect of incentive size remains unclear.2 This study examines the effect of cash incentives on dermatologist response to a mailed questionnaire and its cost-effectiveness.

As part of a study about preferences for psoriasis treatment, we surveyed 1000 dermatologists,3 randomizing each to receive an initial questionnaire packet with either $5 or $10 (with a note offering this token of appreciation) or no cash (Fig 1). Using a modified Dillman Tailored Design method,4 we sent postcard reminders and duplicate surveys to nonrespondents after the initial mailing. The study was approved by the University of Pennsylvania Institutional Review Board.

We compared survey response with respect to physician characteristics and incentives and performed logistic regression to evaluate interactions among possible predictors of response determined a priori. We calculated cost per response and incremental cost-effectiveness, considering only incentive and material costs ($1/questionnaire without incentive, $1.10/questionnaire with incentive, $0.75/postcard, $0.50/response postage), and performed sensitivity analysis by maximizing material costs. Confidence intervals (CIs) were calculated by using bootstrap and Fieller’s theorem methods.

The overall response rate was 39.1%, with rates of 25%, 43% (odds ratio [OR], 2.26; 95% CI, 1.61-3.16), and 48% (OR, 2.80; 95% CI, 1.99-3.93) in the $0, $5, and $10 groups, respectively (see Fig 1). However, response rates in the $5 and $10 groups did not differ significantly (P = .17, Fisher’s exact test). In multivariate logistic regression, National Psoriasis Foundation (NPF) membership (OR, 2.48; 95% CI, 1.89-3.26) and receipt of incentive (OR, 2.63; 95% CI, 1.94-3.55) were significant predictors of survey response, whereas sex and duration of practice were nonsignificant.3
Inclusion of $5 instead of $0 or of $10 rather than $5 cost $27.35 (95% CI, 19.33-45.93) and $88.83 (37.00-244.89) per extra response, respectively (Table I); the latter CI indicates that at an investigator’s willingness-to-pay between $0 and $37 per extra response, we can be 95% confident that $10 incentives represent bad value compared with $5 incentives. In the sensitivity analysis, once questionnaire and postcard costs surpassed $1.88 and $1.63, respectively, the cost per response in the $0 group exceeded that in the $5 group; at these material costs and higher, the use of $5 incentives, compared with no incentive, thus represents better value when investigators are concerned with increasing the total number of responses.

Although dermatologists have generally low response rates to surveys, they respond just as positively to monetary incentives as other specialists. The higher response among NPF members also supports previous findings that topical salience influences survey response. Moreover, financial incentives can be cost effective, particularly when survey costs are high. However, increasing incentive size leads to diminishing returns and amounts over $5 may be less cost effective.

To engage dermatologists in survey-based research, investigators should consider using small financial incentives. Future studies should investigate response rates in other surveys of dermatologists to further assess the generalizability of our results.

---

**Table I. Cost per completed survey and incremental cost-effectiveness by incentive group**

<table>
<thead>
<tr>
<th>Incentive</th>
<th>$0</th>
<th>$5</th>
<th>$10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost</td>
<td>$1082.50</td>
<td>$2719.65</td>
<td>$4348.55</td>
</tr>
<tr>
<td>Cost/response* (95% CI)</td>
<td>$13.04 (10.87 to 16.20)</td>
<td>$19.02 (16.85 to 21.79)</td>
<td>$27.01 (24.15 to 30.60)</td>
</tr>
<tr>
<td>Incremental cost-effectiveness† (95% CI)</td>
<td>—</td>
<td>$27.35 (19.33 to 45.93)</td>
<td>$88.83 (37.00 to 244.89)</td>
</tr>
<tr>
<td>Cost/response at maximal costs‡ (95% CI)</td>
<td>$41.77 (34.64 to 52.14)</td>
<td>$34.15 (29.99 to 39.46)</td>
<td>$39.87 (35.36 to 45.53)</td>
</tr>
<tr>
<td>Incremental cost-effectiveness at maximal costs (95% CI)</td>
<td>—</td>
<td>$23.54 (15.72 to 41.59)</td>
<td>$84.08 (33.10 to 243.54)</td>
</tr>
</tbody>
</table>

CI, Confidence interval.

*Cost per response was calculated by dividing the total expenditures per incentive group by the number of returned surveys in that group.
†Incremental cost-effectiveness was calculated by dividing the difference in mean total cost per subject between two incentive groups by the difference in response rate between the two groups.
‡In our sensitivity analysis, maximal costs were calculated by adding $2 to both the questionnaire and postcard mailing costs per person.
We are indebted to Dr Henry A. Glick for his assistance in cost analysis and to Dr Sinéad M. Langan for her assistance in data analysis.

Joy Wan, BA, Katrina Abuabara, MD, MA, Daniel B. Shin, BA, Andrea B. Troxel, ScD, Bruce F. Bebo, Jr, PhD, and Joel M. Gelfand, MD, MSCE

Department of Dermatology, Center for Clinical Epidemiology and Biostatistics, and Department of Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia and National Psoriasis Foundation, Portland, Oregon

Funding sources: This work was supported by grants from NIAMS RC1-AR058204 (to J.M.G.), the Doris Duke Clinical Research Fellowship (to K.A.), and NIH Training Grant T32-AR07465 (to J.W.).

Conflicts of interest: None declared.

Correspondence to: Joel M. Gelfand, MD, MSCE, 1471 Penn Tower, One Convention Avenue, Philadelphia, PA 19104

E-mail: Joel.Gelfand@uphs.upenn.edu

REFERENCES


doi:10.1016/j.jaad.2011.03.017

Conflict of interest and disclosure: Analysis of American Academy of Dermatology Annual Meetings

To the Editor: When individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of continuing medical education (CME) about the products or services of that commercial interest, conflicts of interest (COI) exist. Faculty, planners, and speakers at national dermatology CME meetings often have COI. It is the job of CME providers like the American Academy of Dermatology (AAD) to resolve COI to avoid commercial bias.1 Disclosure of these relationships is an important first step in the process to identify COI. Disclosure slides at the beginning of presentations also remind speakers and audiences of these relationships and allow audiences to decide whether commercial bias exists.1 The study’s objectives were to determine usage rates of speaker disclosure slides in large audience sessions at the AAD annual meeting before and after implementation of various reminder systems and to identify rates of COI disclosed over a 4-year period.

Submitted electronic slides from faculty presentations at large sessions (courses, symposia, and forums) at the 2005, 2006, and 2008 AAD Annual Meetings were reviewed. For each presentation, the first 6 slides were reviewed. Educational session type, presence of disclosure slide, slide type (AAD-provided disclosure template or faculty-created slide), and disclosure content (a statement of no COI or of one or more industry relationships) were recorded for each. Four speaker disclosure reminder systems were identified including e-mail reminders from AAD to speakers with standardized PowerPoint disclosure slide templates, mailed or e-mailed instructions reminding speakers to include disclosure slides on computer desktop in speaker ready room, and disclosure slides in faculty presentations.

Table 1. Reminder systems by AAD annual meeting year

<table>
<thead>
<tr>
<th>Lead time for e-mailing slide templates</th>
<th>2005</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker packet reminder format</td>
<td>Paper</td>
<td>Paper</td>
<td>Electronic</td>
</tr>
<tr>
<td>Disclosure slide reminder sign in speaker ready room</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Disclosure slide template available on computer desktop in speaker ready room</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Including disclosure slides in faculty presentations</td>
<td>Encouraged</td>
<td>Required</td>
<td>Required</td>
</tr>
</tbody>
</table>

Conflict of interest and disclosure: Analysis of American Academy of Dermatology Annual Meetings

To the Editor: When individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of continuing medical education (CME) about the products or services of that commercial interest, conflicts of interest (COI) exist. Faculty, planners, and speakers at national dermatology CME meetings often have COI. It is the job of CME providers like the American Academy of Dermatology (AAD) to resolve COI to avoid commercial bias.1 Disclosure of these relationships is an important first step in the process to identify COI. Disclosure slides at the beginning of presentations also remind speakers and audiences of these relationships and allow audiences to decide whether commercial bias exists.1 The study’s objectives were to determine usage rates of speaker disclosure slides in large audience sessions at the AAD annual meeting before and after implementation of various reminder systems and to identify rates of COI disclosed over a 4-year period.

Submitted electronic slides from faculty presentations at large sessions (courses, symposia, and forums) at the 2005, 2006, and 2008 AAD Annual Meetings were reviewed. For each presentation, the first 6 slides were reviewed. Educational session type, presence of disclosure slide, slide type (AAD-provided disclosure template or faculty-created slide), and disclosure content (a statement of no COI or of one or more industry relationships) were recorded for each. Four speaker disclosure reminder systems were identified including e-mail reminders from AAD to speakers with standardized PowerPoint disclosure slide templates, mailed or e-mailed instructions reminding speakers to include disclosure slides, an eye-level 3-foot printed reminder sign in the entryway of the speaker-ready room, and a downloadable disclosure slide template located on the speaker-ready room computer desktops for disclosure slide insertion on site. The timing of these reminders for the years studied is shown in Table 1.